The verdict
Our read at a glance.
Whether angiotensin II's approved benefit is understood narrowly, as a rescue vasopressor that raises blood pressure in adults with septic or other distributive shock when standard vasopressors are not enough, rather than a proven way to lower death from shock.
- The signal
- In a randomized trial of patients whose dangerously low blood pressure was not responding to standard vasopressors, angiotensin II raised blood pressure to target in more patients than placebo. The trial measured blood-pressure response, not survival.
- The unknown
- Whether raising blood pressure with angiotensin II actually improves survival or other outcomes, which patients benefit most, and how to weigh its blood-clot risk.
- Our read
- A last-line blood-pressure rescue for shock in intensive care. Angiotensin II reliably raises blood pressure when standard vasopressors fall short, but its approval rested on that blood-pressure response, not on proven survival benefit, and it carries a real clot risk. It is a narrow critical-care tool, nothing more.
The mechanism
How it works.
Angiotensin II is a natural hormone in the system that controls blood pressure, the renin-angiotensin system. The drug is a synthetic copy of it. When infused, it binds a receptor called AT1 on the muscle in blood-vessel walls and makes those vessels tighten, which raises blood pressure; it also nudges the body to hold onto salt and water. In distributive shock, such as sepsis, blood vessels go slack and blood pressure collapses; adding angiotensin II gives another push to constrict the vessels when the standard drugs are not keeping up.
Safety & regulatory boundary
The consequential part.
Angiotensin II carries a warning for blood clots in both arteries and veins, and clot-prevention measures are advised during use. It is a continuous-infusion hospital drug for adults in shock in intensive care, given by specialists, not an outpatient or wellness treatment. Giapreza is approved specifically as an add-on vasopressor for septic or other distributive shock.
What's next
What we're watching.
Trials looking at survival and other clinical outcomes rather than just blood pressure, which shock patients benefit most, and real-world safety including clot risk.
Context
Why this is discussed.
Angiotensin II is one of the body's own blood-pressure-raising hormones, turned into a drug for the sickest patients in shock. It matters as another tool when the usual vasopressors cannot keep blood pressure up in intensive care.
The evidence base
12 cited references.
Regulatory & labels1
La Jolla Pharmaceutical Company (FDA label) · 2024
Registered trials2
ClinicalTrials.gov · PHASE4 · ACTIVE_NOT_RECRUITING · 2022-04-08
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2026-07
Indexed literature (PubMed)9
Khanna A et al. · N Engl J Med · 2017
Delaney A et al. · Intensive Care Med · 2026
Russell JA · Intensive Care Med · 2019
Russell JA et al. · Semin Respir Crit Care Med · 2021
Bellomo R et al. · Am J Respir Crit Care Med · 2020
Wieruszewski PM et al. · Crit Care · 2023
Jentzer JC et al. · Chest · 2018
Wieruszewski PM et al. · Chest · 2021
Kotani Y et al. · Crit Care · 2024
Keep reading